Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110

Cancer Immunology, Immunotherapy

Volumn 56, Issue 7, 2007, Pages 1097-1105

  Kim, Hyung L ^a   Sun, Xiaolei ^a   Subjeck, John R ^a   Wang, Xiang Yang ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Carbonic anhydrase IX; Heat shock protein; Heat shock protein 110; Renal cell carcinoma; RENCA; Tumor vaccine

Indexed keywords

CANCER VACCINE; CARBONATE DEHYDRATASE IX; DNA VACCINE; GLUCOSE REGULATED PROTEIN 170; GLUCOSE REGULATED PROTEIN 170 CARBONIC ANHYDRASE 9 COMPLEX; HEAT SHOCK PROTEIN 110; HEAT SHOCK PROTEIN 110 CARBONIC ANHYDRASE 9 COMPLEX; PLASMID VECTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DNA VECTOR; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG SPECIFICITY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMORAL IMMUNITY; IN VITRO STUDY; INNATE IMMUNITY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; HSP110 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; PLASMIDS; RECOMBINANT PROTEINS;

EID: 34247576347     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0258-z     Document Type: Article

References (36)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10-30
2. Bukowski RM (2000) Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Semin Oncol 27:204-212
3. Figlin RA (1999) Renal cell carcinoma: management of advanced disease (discussion 386-387). J Urol 161:381-386
4. Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G (1997) High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am 3(Suppl1):S70-S72
5. Neumann E, Engelsberg A, Decker J, Storkel S, Jaeger E, Huber C, Seliger B (1998) Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res 58:4090-4095
6. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9:802-811
7. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J, Warnaar SO (1986) Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 38:489-494
8. Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI, Stanbridge EJ (2001) Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158:905-919
9. Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ et al (1993) Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 11:738-750
10. Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, Kruit W, Melchior S, Mala C, Ullrich S, De Mulder P, Mulders PF, Beck J (2004) A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 90:985-990
11. Kim HL, Pantuck AJ, Zomorodian N, Belldegrun AS (2003) Monoclonal antibody (MAB) in patients with advanced cancer. Curr Urol Rep 4:11-12
12. Lindquist S, Craig EA (1988) The heat-shock proteins. Annu Rev Genet 22:631-677
13. Manjili MH, Wang XY, Chen X, Martin T, Repasky EA, Henderson R, Subjeck JR (2003) HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 171:4054-4061
14. Wang XY, Chen X, Manjili MH, Repasky E, Henderson R, Subjeck JR (2003) Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100. Cancer Res 63:2553-2560
15. Wang XY, Kazim L, Repasky EA, Subjeck JR (2001) Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J Immunol 166:490-497
16. Oh HJ, Chen X, Subjeck JR (1997) Hsp110 protects heat-denatured proteins and confers cellular thermoresistance. J Biol Chem 272:31636-31640
17. Park J, Easton DP, Chen X, MacDonald IJ, Wang XY, Subjeck JR (2003) The chaperoning properties of mouse grp170, a member of the third family of hsp70 related proteins. Biochemistry 42:14893-14902
18. Moroi Y, Mayhew M, Trcka J, Hoe MH, Takechi Y, Hartl FU, Rothman JE, Houghton AN (2000) Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proc Natl Acad Sci USA 97:3485-3490
19. MacAry PA, Javid B, Floto RA, Smith KG, Oehlmann W, Singh M, Lehner PJ (2004) HSP70 peptide binding mutants separate antigen delivery from dendritic cell stimulation. Immunity 20:95-106
20. Tobian AA, Canaday DH, Harding CV (2004) Bacterial heat shock proteins enhance class II MHC antigen processing and presentation of chaperoned peptides to CD4+ T cells. J Immunol 173:5130-5137
21. Vissers JL, De Vries IJ, Engelen LP, Scharenborg NM, Molkenboer J, Figdor CG, Oosterwijk E, Adema GJ (2002) Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T lymphocytes. Int J Cancer 100:441-444
22. Manjili MH, Henderson R, Wang XY, Chen X, Li Y, Repasky E, Kazim L, Subjeck JR (2002) Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res 62:1737-1742
23. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM et al (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90
24. Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, Kobayashi K, Miura T, Moriyama M, Nagashima Y, Nakatani Y, Kubota Y, Kondo K (2002) VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 94:1569-1575
25. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM et al (1994) Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91:9700-9704
26. Gething MJ, Sambrook J (1992) Protein folding in the cell. Nature 355:33-45
27. Haas IG (1991) BiP - a heat shock protein involved in immunoglobulin chain assembly. Curr Top Microbiol Immunol 167:71-82
28. Klein G, Sjogren HO, Klein E, Hellstrom KE (1960) Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 20:1561-1572
29. Udono H, Srivastava PK (1994) Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol 152:5398-5403
30. Castelli C, Ciupitu AM, Rini F, Rivoltini L, Mazzocchi A, Kiessling R, Parmiani G (2001) Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 61:222-227
31. Amato R, Wood L, Savary C, Wood C, Hawkins E, Reitsma D, Srivastava PK. (2000) Patients with renal cell carcinoma (RCC) using autologous tumor-derived heat shock protein-peptide complex (HSPPC-96) with or without interleukin-2 (IL-2). Presented at: ASCO A1782
32. Assikis VJ, Daliani D, Pagliaro L, Wood C, Perez C, Logothetis C, Papandreou C, Hawkins ES, Srivastava PK (2003) Phase II study of an autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC). Presented at: ASCO A1552
33. Wood C, Escudier B, Gorelov S, Krajka K, Lacombe L, Fossa S, Hoos A, Flanigan R, Figlin RA, Srivastava PK. (2004) A multicenter randomized study of adjuvant heat-shock protein peptide-complex 96 (HSPPC-96) vaccine in patients with high-risk of recurrence after nephrectomy for renal cell carcinoma (RCC) - a preliminary report. Presented at: ASCO A2618
34. Udono H, Yamano T, Kawabata Y, Ueda M, Yui K (2001) Generation of cytotoxic T lymphocytes by MHC class I ligands fused to heat shock cognate protein 70. Int Immunol 13:1233-1242
35. Suzue K, Zhou X, Eisen HN, Young RA (1997) Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc Natl Acad Sci USA 94:13146-13151
36. Anthony LS, Wu H, Sweet H, Turnnir C, Boux LJ, Mizzen LA (1999) Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule. Vaccine 17:373-383